强直性肌营养不良：治疗方法
Myotonic dystrophy: approach to therapy.
作者信息
Thornton Charles A, Wang Eric, Carrell Ellie M
机构信息
Department of Neurology, University of Rochester, Rochester 14642, NY, United States.
Department of Molecular Genetics & Microbiology, Center for NeuroGenetics, University of Florida, Gainesville, FL, United States.
出版信息
Curr Opin Genet Dev. 2017 Jun;44:135-140. doi: 10.1016/j.gde.2017.03.007. Epub 2017 Apr 1.
Abstract
Myotonic dystrophy (DM) is a dominantly-inherited genetic disorder affecting skeletal muscle, heart, brain, and other organs. DM type 1 is caused by expansion of a CTG triplet repeat in DMPK, whereas DM type 2 is caused by expansion of a CCTG tetramer repeat in CNBP. In both cases the DM mutations lead to expression of dominant-acting RNAs. Studies of RNA toxicity have now revealed novel mechanisms and new therapeutic targets. Preclinical data have suggested that RNA dominance is responsive to therapeutic intervention and that DM therapy can be approached at several different levels. Here we review recent efforts to alleviate RNA toxicity in DM.
摘要
强直性肌营养不良（DM）是一种常染色体显性遗传的疾病，会影响骨骼肌、心脏、大脑及其他器官。1型强直性肌营养不良是由DMPK基因中CTG三联体重复序列的扩增引起的，而2型强直性肌营养不良则是由CNBP基因中CCTG四联体重复序列的扩增引起的。在这两种情况下，DM突变都会导致显性作用RNA的表达。目前对RNA毒性的研究揭示了新的机制和新的治疗靶点。临床前数据表明，RNA显性对治疗干预有反应，并且可以在几个不同层面上进行DM治疗。在这里，我们综述了最近为减轻DM中RNA毒性所做的努力。
相似文献
1
Myotonic dystrophy: approach to therapy.强直性肌营养不良：治疗方法
Curr Opin Genet Dev. 2017 Jun;44:135-140. doi: 10.1016/j.gde.2017.03.007. Epub 2017 Apr 1.
2
Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.强直性肌营养不良：1型和2型强直性肌营养不良之间的临床与分子相似性
Curr Neurol Neurosci Rep. 2002 Sep;2(5):465-70. doi: 10.1007/s11910-002-0074-6.
3
Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.强直性肌营养不良症：临床方面、遗传学、病理学及分子发病机制的最新进展
Biochim Biophys Acta. 2015 Apr;1852(4):594-606. doi: 10.1016/j.bbadis.2014.05.019. Epub 2014 May 29.
4
Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.肌强直性营养不良 1 型治疗的嵌合 LNA/2'-O-甲基位阻物的系统评价。
Nucleic Acid Ther. 2020 Apr;30(2):80-93. doi: 10.1089/nat.2019.0811. Epub 2019 Dec 23.
5
Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.在发育过程中，有义链和反义链 DMPK RNA 病灶在 DM1 组织中积累。
PLoS One. 2015 Sep 4;10(9):e0137620. doi: 10.1371/journal.pone.0137620. eCollection 2015.
6
Myotonic dystrophy: RNA pathogenesis comes into focus.强直性肌营养不良症：RNA发病机制成为焦点。
Am J Hum Genet. 2004 May;74(5):793-804. doi: 10.1086/383590. Epub 2004 Apr 2.
7
Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.强直性肌营养不良患者的富克斯角膜内皮营养不良与RNA病灶
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4579-4585. doi: 10.1167/iovs.17-22350.
8
Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat.肌强直性营养不良基因座的反义转录产生含有和不含有（CAG）n 重复的低丰度 RNA。
RNA Biol. 2017 Oct 3;14(10):1374-1388. doi: 10.1080/15476286.2017.1279787. Epub 2017 Jan 19.
9
[Myotonic dystrophy - a new insight into a well-known disease].[强直性肌营养不良——对一种知名疾病的新见解]
Neurol Neurochir Pol. 2010 May-Jun;44(3):264-76. doi: 10.1016/s0028-3843(14)60041-4.
10
Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9.使用 CRISPR/Cas9 治疗 1 型肌强直性营养不良症的基因组编辑
Mol Ther. 2018 Nov 7;26(11):2617-2630. doi: 10.1016/j.ymthe.2018.09.003. Epub 2018 Sep 11.
引用本文的文献
1
Chemical Modifications in Nucleic Acid Therapeutics.核酸疗法中的化学修饰
Methods Mol Biol. 2025;2965:57-126. doi: 10.1007/978-1-0716-4742-4_3.
2
A KIF1C-CNBP motor-adaptor complex for trafficking mRNAs to cell protrusions.一种用于将mRNA转运至细胞突起的KIF1C-CNBP马达-衔接蛋白复合体。
Cell Rep. 2025 Mar 25;44(3):115346. doi: 10.1016/j.celrep.2025.115346. Epub 2025 Feb 20.
3
A Novel Class of FKBP12 Ligands Rescues Premature Aging Phenotypes Associated with Myotonic Dystrophy Type 1.一类新型FKBP12配体可挽救与1型强直性肌营养不良相关的早衰表型。
Cells. 2024 Nov 22;13(23):1939. doi: 10.3390/cells13231939.
4
Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.1型强直性肌营养不良症使用红霉素治疗：一项多中心、随机、双盲、安慰剂对照的2期试验。
EClinicalMedicine. 2023 Dec 26;67:102390. doi: 10.1016/j.eclinm.2023.102390. eCollection 2024 Jan.
5
Acute leg pain and weakness in pregnancy: A new diagnosis of myotonic dystrophy.妊娠期急性腿痛和肌无力：强直性肌营养不良的新诊断
Obstet Med. 2023 Dec;16(4):253-255. doi: 10.1177/1753495X221109738. Epub 2022 Jun 30.
6
Muscleblind-like proteins use modular domains to localize RNAs by riding kinesins and docking to membranes.肌萎缩蛋白样蛋白通过与驱动蛋白结合并停靠在膜上，利用模块化结构域将 RNA 定位。
Nat Commun. 2023 Jun 9;14(1):3427. doi: 10.1038/s41467-023-38923-6.
7
Specific -promoter targeting by CRISPRi reverses myotonic dystrophy type 1-associated defects in patient muscle cells.通过CRISPRi进行的特异性启动子靶向可逆转1型强直性肌营养不良患者肌肉细胞中的相关缺陷。
Mol Ther Nucleic Acids. 2023 May 13;32:857-871. doi: 10.1016/j.omtn.2023.05.007. eCollection 2023 Jun 13.
8
Block or degrade? Balancing on- and off-target effects of antisense strategies against transcripts with expanded triplet repeats in DM1.阻断还是降解？平衡针对DM1中具有扩展三联体重复序列的转录本的反义策略的靶向和脱靶效应。
Mol Ther Nucleic Acids. 2023 Apr 20;32:622-636. doi: 10.1016/j.omtn.2023.04.010. eCollection 2023 Jun 13.
9
Therapeutic targeting of CNBP phase separation inhibits ribosome biogenesis and neuroblastoma progression via modulating SWI/SNF complex activity.靶向 CNBP 液-液相分离抑制核糖体生物发生和神经母细胞瘤进展的治疗作用，通过调节 SWI/SNF 复合物的活性。
Clin Transl Med. 2023 Apr;13(4):e1235. doi: 10.1002/ctm2.1235.
10
Associations between lower extremity muscle fat fraction and motor performance in myotonic dystrophy type 2: A pilot study.2 型肌强直性营养不良下肢肌肉脂肪分数与运动表现的相关性：一项初步研究。
Muscle Nerve. 2023 Jun;67(6):506-514. doi: 10.1002/mus.27821. Epub 2023 Apr 3.
本文引用的文献
1
Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.靶向失调的AMPK/mTORC1信号通路可改善I型强直性肌营养不良症的肌肉功能。
J Clin Invest. 2017 Feb 1;127(2):549-563. doi: 10.1172/JCI89616. Epub 2017 Jan 9.
2
Precise small-molecule recognition of a toxic CUG RNA repeat expansion.对有毒的CUG RNA重复扩增进行精确的小分子识别。
Nat Chem Biol. 2017 Feb;13(2):188-193. doi: 10.1038/nchembio.2251. Epub 2016 Dec 12.
3
Mechanistic determinants of MBNL activity.MBNL活性的机制决定因素。
Nucleic Acids Res. 2016 Dec 1;44(21):10326-10342. doi: 10.1093/nar/gkw915. Epub 2016 Oct 12.
4
Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy.全身性肽介导的寡核苷酸疗法可提高脊髓性肌萎缩症的长期生存率。
Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10962-7. doi: 10.1073/pnas.1605731113. Epub 2016 Sep 12.
5
Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice.Dmpk基因缺失或反义敲低不会损害小鼠的心脏或骨骼肌功能。
Hum Mol Genet. 2016 Oct 1;25(19):4328-4338. doi: 10.1093/hmg/ddw266. Epub 2016 Aug 13.
6
Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts.Spt4选择性地调节C9orf72正义和反义突变转录本的表达。
Science. 2016 Aug 12;353(6300):708-12. doi: 10.1126/science.aaf7791.
7
A Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy.一种由扩展三联体（CUG）重复序列介导的蛋白质隔离的强效抑制剂，在强直性肌营养不良果蝇模型中显示出表型改善。
ChemMedChem. 2016 Jul 5;11(13):1428-35. doi: 10.1002/cmdc.201600081. Epub 2016 Jun 1.
8
Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy.口服红霉素可降低肌强直性营养不良的 RNA 毒性。
Ann Clin Transl Neurol. 2015 Dec 10;3(1):42-54. doi: 10.1002/acn3.271. eCollection 2016 Jan.
9
Actinomycin D Specifically Reduces Expanded CUG Repeat RNA in Myotonic Dystrophy Models.放线菌素D特异性降低强直性肌营养不良模型中扩增的CUG重复RNA。
Cell Rep. 2015 Dec 22;13(11):2386-2394. doi: 10.1016/j.celrep.2015.11.028. Epub 2015 Dec 10.
10
The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA.核糖核酸酶 H1 依赖性反义寡核苷酸诱导的 RNA 降解的分子机制中主要步骤的速率。
Nucleic Acids Res. 2015 Oct 15;43(18):8955-63. doi: 10.1093/nar/gkv920. Epub 2015 Sep 17.
Zotero 插件